A physiologically based pharmacokinetic model of rifampin in mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1763-1771

  Lyons, Michael A ^a   Reisfeld, Brad ^b   Yang, Raymond S H ^a   Lenaerts, Anne J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Engineering Research Center and Hydraulics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG LIVER LEVEL; IMMUNE RESPONSE; INDIVIDUALITY; KIDNEY; LUNG; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; COMPUTER SIMULATION; MICE; MONTE CARLO METHOD; RIFAMPIN; TUBERCULOSIS;

EID: 84875191395     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01567-12     Document Type: Article

References (70)

1. Dye C. 2006. Global epidemiology of tuberculosis. Lancet 367:938-940.
2. Ginsberg AM. 2010. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb.) 90:162-167.
3. Lenaerts AJ, Degroote MA, Orme IM. 2008. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol. 16:48-54.
4. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. 2011. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:239-245.
5. Nuermberger E. 2008. Using animal models to develop new treatments for tuberculosis. Semin. Respir. Crit. Care Med. 29:542-551.
6. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772.
7. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205:595-602.
8. Spigelman M, Woosley R, Gheuens J. 2010. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int. J. Tuberc. Lung Dis. 14:663-664.
9. De Groote MA, Gilliland JC, Wells CL, Brooks EJ, Woolhiser LK, Gruppo V, Peloquin CA, Orme IM, Lenaerts AJ. 2011. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:1237-1247.
10. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
11. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:3664-3668.
12. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485-5492.
13. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, Califano A, D'Argenio DZ, Iyengar R, Jusko WJ, Lalonde R, Lauffenburger DA, Shoichet B, Stevens JL, Subramaniam S, Van der Graaf P, Vicini P. 2011. Quantitativeandsystemspharmacologyinthepost-genomicera:newapproaches to discovering drugsandunderstanding therapeutic mechanisms.AnNIHWhite Paper by the QSP Workshop Group-October 2011. National Institutes of Health, Bethesda, MD. http://www.nigms.nih.gov/NR/rdonlyres/8ECB1F7C-BE3B-431F-89E6-A43411811AB1/0/ SystemsPharmaWPSorger2011.pdf.
14. Day J, Schlesinger LS, Friedman A. 2010. Tuberculosis research: going forward with a powerful "translational systems biology" approach. Tuberculosis (Edinb.) 90:7-8.
15. Marino S, Linderman JJ, Kirschner DE. 2011. A multifaceted approach to modeling the immune response in tuberculosis. Wiley Interdiscip. Rev. Syst. Biol. Med. 3:479-489.
16. Friedman A, Turner J, Szomolay B. 2008. A model on the influence of age on immunity to infection with Mycobacterium tuberculosis. Exp. Gerontol. 43:275-285.
17. Goutelle S, Bourguignon L, Jelliffe RW, Conte JE, Jr, Maire P. 2011. Mathematical modeling of pulmonary tuberculosis therapy: insights from a prototype model with rifampin. J. Theor. Biol. 282:80-92.
18. Magombedze G, Garira W, Mwenje E. 2006. Mathematical modeling of chemotherapy of human TB infection. J. Biol. Syst. 14:509-553.
19. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention, the Infectious Diseases Society. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
20. Lienhardt C, Vernon A, Raviglione MC. 2010. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr. Opin. Pulm. Med. 16:186-193.
21. Basaraba RJ. 2008. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb.) 88(Suppl 1):S35-S47.
22. Bois F, Maszle D. 1997. MCSim: a simulation program. J. Stat. Softw. 2:1-60.
23. Hindmarsh AC. 1983. ODEPACK, a systemized collection of ODE solvers, p 55-64. In Stepleman RS, Carver M, Peskin R, Ames WF, Vichnevetsky R (ed), Scientific computing, IMACS transactions of scientific computation, vol 1. North-Holland Pub. Co., Amsterdam, Netherlands.
24. Gilks WR, Best NG, Tan KKC. 1995. Adaptive rejection metropolis sampling within Gibbs sampling. Appl. Stat. 44:455-472.
25. R Development Core Team. 2012. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.Rproject.org.
26. Binda G, Domenichini E, Gottardi A, Orlandi B, Ortelli E, Pacini B, Fowst G. 1971. Rifampicin, a general review. Arzneimittelforschung 21: 1907-1977.
27. Bruzzese T, Rimaroli C, Bonabello A, Mozzi G, Ajay S, Cooverj ND. 2000. Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species. Arzneimittelforschung 50:60-71.
28. Saito H, Tomioka H. 1989. Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice. Antimicrob. Agents Chemother. 33:429-433.
29. Yang X, Matheny CJ, White NR, Pollack GM. 2003. Quantitative analysis of rifampin for evaluating pharmacokinetics and tissue distribution in mice. Pharm. Sci. 5:4.
30. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. 2011. Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl. Trop. Dis. 5:e933. doi:10.1371/journal.pntd.0000933.
31. Dickinson J, Guy A, Mitchison DA. 1992. Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob. Agents Chemother. 36: 2066-2067.
32. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, Roscigno G, Grosset J. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148:1541-1546.
33. Raybon JJ, Pray D, Morgan DG, Zoeckler M, Zheng M, Sinz M, Kim S. 2011. Pharmacokinetic-pharmacodynamic modeling of rifampicinmediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice. J. Pharmacol. Exp. Ther. 337:75-82.
34. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi:10.1371/journal.pmed.0040344.
35. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331-4340.
36. Burman WJ, Gallicano K, Peloquin C. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
37. Archer GL, Armstrong BC, Kline BJ. 1982. Rifampin blood and tissue levels in patients undergoing cardiac valve surgery. Antimicrob. Agents Chemother. 21:800-803.
38. Kenny MT, Strates B. 1981. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab. Rev. 12:159-218.
39. Kropec A, Daschner FD. 1991. Penetration into tissues of various drugs active against gram-positive bacteria. J. Antimicrob. Chemother. 27(Suppl B):9-15.
40. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 1985. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63:1205-1211.
41. Frantz J. g3data (version 1.5.2). http://www.frantz.fi/software/g3data. php.
42. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45:511-542.
43. Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lave T. 2003. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J. Pharm. Sci. 92:1990-2007.
44. Bois FY. 2000. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108(Suppl 2):307-316.
45. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126.
46. Clewell RA, Clewell HJ, III. 2008. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul. Toxicol. Pharmacol. 50:129-143.
47. Marino DJ. 2012. Age-specific absolute and relative organ weight distributions for B6C3F1 mice. J. Toxicol. Environ. Health A 75:76-99.
48. Portier CJ, Kaplan NL. 1989. Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. Fundam. Appl. Toxicol. 13:533-544.
49. Thomas RS, Yang RS, Morgan DG, Moorman MP, Kermani HR, Sloane RA, O'Connor RW, Adkins B, Jr, Gargas ML, Andersen ME. 1996. PBPK modeling/Monte Carlo simulation of methylene chloride kinetic changes in mice in relation to age and acute, subchronic, and chronic inhalation exposure. Environ. Health Perspect. 104:858-865.
50. Arms AD, Travis CC. 1988. Reference physiological parameters in pharmacokinetic modelling. US Environmental Protection Agency report no. EPA/600/6-88/004. US Environmental Protection Agency, Washington, DC.
51. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. 1971. Methotrexate pharmacokinetics. J. Pharm. Sci. 60:1128-1133.
52. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13:407-484.
53. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker Inc., New York, NY.
54. Gilks WR, Richardson S, Spiegelhalter DJ (ed). 1996. Markov chain Monte Carlo in practice. Chapman & Hall/CRC, Boca Raton, FL.
55. Cheng S, Bois FY. 2011. A mechanistic modeling framework for predicting metabolic interactions in complex mixtures. Environ. Health Perspect. 119:1712-1718.
56. Baciewicz AM, Chrisman CR, Finch CK, Self TH. 2008. Update on rifampin and rifabutin drug interactions. Am. J. Med. Sci. 335:126-136.
57. Yang RS, El-Masri HA, Thomas RS, Dobrev ID, Dennison JE, Jr, Bae DS, Campain JA, Liao KH, Reisfeld B, Andersen ME, Mumtaz M. 2004. Chemical mixture toxicology: from descriptive to mechanistic, and going on to in silico toxicology. Environ. Toxicol. Pharmacol. 18:65-81.
58. Edginton AN, Ahr G, Willmann S, Stass H. 2009. Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 48:181-187.
59. Reisfeld B, Metzler CP, Lyons MA, Mayeno AN, Brooks EJ, Degroote MA. 2012. A physiologically based pharmacokinetic model for capreomycin. Antimicrob. Agents Chemother. 56:926-934.
60. Reddy M, Yang RS, Andersen ME, Clewel HJ (ed). 2005. Physiologically based pharmacokinetic modeling: science and applications. John Wiley & Sons, Inc., Hoboken, NJ.
61. Tanaka C, Kawai R, Rowland M. 1999. Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats. J. Pharmacokinet. Biopharm. 27:597-623.
62. Shah DK, Betts AM. 2012. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J. Pharmacokinet. Pharmacodyn. 39:67-86.
63. Yang RS, Chang LW, Wu JP, Tsai MH, Wang HJ, Kuo YC, Yeh TK, Yang CS, Lin P. 2007. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ. Health Perspect. 115:1339-1343.
64. Krishnan K, Johanson G. 2005. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 23:31-53.
65. Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE, Jr, Jelliffe RW. 2009. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 53:2974-2981.
66. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE, III, Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56:446-457.
67. Furesz S. 1970. Chemical and biological properties of rifampicin. Antibiot. Chemother. 16:316-351.
68. Acocella G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127.
69. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148.
70. Marino DJ, Clewell HJ, Gentry PR, Covington TR, Hack CE, David RM, Morgott DA. 2006. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. Regul. Toxicol. Pharmacol. 45:44-54.